Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Alessandra Iurlo, Emanuela Orsi, Daniele Cattaneo, et al.
Oncotarget (2015) Vol. 6, Iss. 32, pp. 33944-33951
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Sulfonamide inhibitors: a patent review 2013-present
İlhami Gülçın, Parham Taslımı
Expert Opinion on Therapeutic Patents (2018) Vol. 28, Iss. 7, pp. 541-549
Closed Access | Times Cited: 127
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Valentín García‐Gutiérrez, Juan Carlos Hernández‐Boluda
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 117
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview
Carlo G. Tocchetti, Christian Cadeddu Dessalvi, Daniela Di Lisi, et al.
Antioxidants and Redox Signaling (2017) Vol. 30, Iss. 18, pp. 2110-2153
Open Access | Times Cited: 113
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Bruno C. Medeiros, Jennifer D. Possick, Michael G. Fradley
Blood Reviews (2018) Vol. 32, Iss. 4, pp. 289-299
Open Access | Times Cited: 76
The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state
Naif M. Alhawiti, Kate L. Burbury, Faith Kwa, et al.
Thrombosis Research (2016) Vol. 145, pp. 54-64
Closed Access | Times Cited: 64
Nilotinib in the Treatment of Chronic Myeloid Leukemia
Tomasz Sacha, Giuseppe Saglio
Future Oncology (2018) Vol. 15, Iss. 9, pp. 953-965
Open Access | Times Cited: 47
Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues
Roshni Bhatnagar, Neal M. Dixit, Eric H. Yang, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 23
Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
Takudzwa Mugiya, Mamosheledi Mothibe, Andile Khathi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Toceranib phosphate‐associated diabetes mellitus in a dog
Shu Min Chan, C. Prior, Christine Sesanto, et al.
Veterinary Record Case Reports (2025)
Closed Access
Chronic myeloid leukemia: Second‐line drugs of choice
Carlo Gambacorti‐Passerini, Andrea Aroldi, Nicoletta Cordani, et al.
American Journal of Hematology (2015) Vol. 91, Iss. 1, pp. 67-75
Open Access | Times Cited: 37
How to manage CML patients with comorbidities
Jorge E. Cortés
Blood (2020) Vol. 136, Iss. 22, pp. 2507-2512
Closed Access | Times Cited: 28
Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US
Meg Franklin, Leah Burns, Samuel Perez, et al.
Current Medical Research and Opinion (2017) Vol. 34, Iss. 2, pp. 353-360
Closed Access | Times Cited: 30
LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis
Xinjian Liu, Hao Yuan, Jing Zhou, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 23
Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update
Chujun Deng, Tak-Ho Lo, Ka-Ying Chan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12376-12376
Open Access | Times Cited: 14
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Hélène Haguet, Jonathan Douxfils, C Chatelain, et al.
TH Open (2018) Vol. 02, Iss. 01, pp. e68-e88
Open Access | Times Cited: 26
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors
P. Buffier, Benjamin Bouillet, Sarra Smati, et al.
Annales d Endocrinologie (2018) Vol. 79, Iss. 5, pp. 574-582
Closed Access | Times Cited: 25
Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors
David M. Ross, Chris Arthur, Kate Burbury, et al.
Internal Medicine Journal (2018) Vol. 48, Iss. S2, pp. 5-13
Open Access | Times Cited: 24
Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper
Nicola Silvestris, Tindara Franchina, Marco Gallo, et al.
ESMO Open (2023) Vol. 8, Iss. 6, pp. 102062-102062
Open Access | Times Cited: 7
Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
Lu Yu, Jing Liu, Xiao‐Jun Huang, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 22
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes
Rana Malek, Stephen N. Davis
Expert Opinion on Investigational Drugs (2016) Vol. 25, Iss. 3, pp. 287-296
Closed Access | Times Cited: 21
Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database
Naoto Okada, Takahiro Niimura, Yoshito Zamami, et al.
Cancer Medicine (2018) Vol. 8, Iss. 1, pp. 174-181
Open Access | Times Cited: 21
How to manage CML patients with comorbidities
Jorge E. Cortés
Hematology (2020) Vol. 2020, Iss. 1, pp. 237-242
Open Access | Times Cited: 18
The Effect of Comorbidities on the Choice of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
Güray Saydam, Rıdvan Ali, Ahmet Muzaffer Demir, et al.
International Journal of Hematologic Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 12
A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia
Khalid Ahmed, Rasha Kaddoura, Mohamed A. Yassin
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 12
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor
Miguel Ángel Gómez-Sámano, Jorge Baquerizo‐Burgos, Marı́a Florencia Coronel, et al.
BMC Endocrine Disorders (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top